Notably, the CheckMate-649 trial, a randomized, open-label, multicenter Phase III study, evaluated nivolumab combined with chemotherapy, nivolumab plus ipilimumab, and single-agent chemotherapy in HER2-negative advanced GC patients. The gene discussed is ERBB2; the disease is gastric cancer.